The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer

진행성 위암 환자에서 1차요법으로 FOLFOX-4 복합화학요법

  • Song, Hong-Suk (Department of Internal Medicine, Keimyung University School of Medicine)
  • 송홍석 (계명대학교 의과대학 혈액종양내과)
  • Published : 2012.01.01
⟨ Previous Next ⟩

Abstract

The FOLFOX-4 regimen as first-line treatment in patients with advanced gastric cancer has not evidence of category 1 for prolongation of survival in patients with advanced gastric cancer. Therefore, the use is preferred in the second line. But, especially in elderly patients, FOLFOX regimen was active and well tolerated with lower toxicities. Further phase III study is warranted to evaluate the evidence for prolongation of survival in elderly patients or combination therapy with target agents in advanced gastric cancer.

Keywords

References

  1. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548. https://doi.org/10.1200/JCO.2002.02.021
  2. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, lecovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442. https://doi.org/10.1200/JCO.2007.13.9378
  3. Cunningham D, Startling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Eng J Med 2008;358:36-46. https://doi.org/10.1056/NEJMoa073149
  4. Bang YJ, Van Custem E, Feyerislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010; 376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X